Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26107873 | 0.84 | HDAC3 (0.65) | HDAC3HDAC6NCOR2NPC1RAB9A | |
| SCHEMBL12402151 | 0.84 | HDAC3 (0.57) | HDAC3HDAC6NCOR2KDM4ENPC1 | |
| SCHEMBL25407073 | 0.82 | IKBKB (0.49) | HDAC3HDAC6NCOR2POLBAOC3 | |
| SCHEMBL17207531 | 0.80 | AOC3 (0.50) | KDM4ENPC1RAB9APOLBATM | |
| SCHEMBL1040640 | 0.79 | HDAC3 (0.56) | HDAC3HDAC6NCOR2KDM4ENPC1 | |
| SCHEMBL1039187 | 0.79 | NR1H2 (0.59) | HDAC3HDAC6NCOR2KDM4ENPC1 | |
| SCHEMBL17541725 | 0.78 | KDM4E (0.55) | KDM4ENPC1RAB9APOLBATM | |
| SCHEMBL29330535 | 0.77 | HDAC3 (0.53) | HDAC3HDAC6NCOR2KDM4EAOC3 | |
| SCHEMBL16364806 | 0.76 | AOC3 (0.51) | KDM4ENPC1RAB9APOLBATM | |
| SCHEMBL4859334 | 0.76 | NR1H2 (0.56) | HDAC3HDAC6NCOR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | UDC IRELAND LTD (IE) | 2015-10-29 | — | — | US | disclosed |
| US-9062084-B2 | Method of forming metal complex compound, and organic electroluminescence device | UDC Ireland (IE) | 2015-06-23 | — | — | US | disclosed |
| EP-2051714-B1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-04-13 | — | — | EP | disclosed |
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-1853596-B1 | NOVEL, LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-2057152-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | Boehringer Ingelheim International GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| EP-2051714-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | Boehringer Ingelheim International GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-7423036-B2 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| WO-2008017637-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017638-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | ADRA1A, ADRA1D, ADRA2A | HDAC3 4317/4885HDAC6 4133/4885NCOR2 3283/4885 |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | NDUFA1, NDUFA6, NDUFA3 | HDAC3 1477/4885HDAC6 713/4885NCOR2 1925/4885 |
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | ZFR, PORCN, OR10J3 | HDAC3 1598/4885HDAC6 1705/4885NCOR2 1505/4885 |
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | ZFR, PORCN, OR10J3 | HDAC3 1598/4885HDAC6 1705/4885NCOR2 1505/4885 |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | ADRB1, ADRA1A, ADRB2 | HDAC3 4657/4885HDAC6 4346/4885NCOR2 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.